Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAVX-010 Phase I Safety and PK Study
NCT03655522Phase 1Completed
- Sponsor
- Algenis
- Start
- May 2015
- Primary completion
- Sep 2015
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in anal fissure and acute pain comparing NAVX-010 with Placebo (2 arms). Primary endpoints: Adverse events related to NAVX-010 at 5 days, Oral body temperature changes at 5 days and 10 more. Started May 2015; status: completed.
02
Drugs
gonyautoxin 2 + gonyautoxin 3
03
Conditions
anal fissureacute pain
Beyond the preview
Go deeper on NCT03655522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03655522.